This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

1 Jul 2011

Anacor Announces Positive Results of AN2728 for Psoriasis

Anacor Pharmaceuticals reports positive results from a mid-stage trial of a drug candidate designed to treat the skin condition psoriasis.

Anacor Pharmaceuticals Inc. has received positive preliminary results from its Phase IIb trial of AN2728 which is used for the treatment of mild-to-moderate plaque-type psoriasis.


AN2728, a boron-based small-molecule compound, reduces the production of inflammatory cytokines associated with psoriasis.


The randomised trial enrolled 68 subjects. Results showed that 26% of subjects in the AN2728 arm achieved Physicians Global Assessment success, compared to 18% in the vehicle arm.


Anacor Pharmaceuticals CEO David Perry said that the seven previous AN2728 trials, combined with the results from this trial, provide them with the data t

Related News